Intra- and inter-familial phenotypic heterogeneity of the m.7510T>C variant
Received Date: Apr 02, 2018 / Accepted Date: Apr 23, 2018 / Published Date: Apr 28, 2018
In a recent article Kytövuori et al. reported a Finnish family with phenotypically variable multiorgan disease manifesting in the brain, ears, and endocrine organs, due to the variant m.7510T>C in the MT-TS1 (tRNA(Ser)) gene with high heteroplasmy. We have the following comments and concerns.
Keywords: Mitochondrial; mtDNA; Phenotype; Genotype; Epilepsy; Heterogeneity; Multisystem
Though the mutation m.7510T>C has been previously reported (Table 1) [1-5], the pathogenicity of this variant is not well supported. Currently it is recommended to assess the pathogenicity of tRNA variants according to the modified Yarham score . According to this tool the variant m.7510T>C scores 9 (>1 independent report: 2, heteroplasmy: 2, segregation with variant: 2, biochemical defect in CI, CIII, or CIV: 0, variant segregation with biochemical defect on single fiber studies: 0, mutant mt-tRNA steady state level studies or evidence of pathogenicity in trans-mitochondrial cybrid studies: 0, evidence of normality in trans-mitochondrial cybrid studies: 0, evolutionary conservation of nucleotide: 2, histopathology: 1), indicating that the variant is only “possibly pathogenic” .
|Sex||f||f||m||f||f||f||m||f=5, m=6||f=16, m=10||f||m||f|
|HP (blood), %||90||99||99||99||homoplasmic||homoplasmic||no||>95||>95||>95|
|HP (muscle), %||np||np||np||99||np||np||np||np||no||np||np||np|
|HP (buccal mucosa), %||np||99||np||np||np||np||np||np||no||np||np||np|
|RLS: Restless Leg Syndrome, HP: Heteroplasmy, Np: Not Provided, ES: DuringElementary School|
Table 1: Intra- and inter-familial phenotypic heterogeneity of the m.7510T>C variants.
The index patient had epilepsy with onset at age 9 years . Why was valproate (VPA) initially chosen? It is well established that VPA, together with carbamazepine, phenytoin, and phenobarbital, is mitochondrion-toxic  and a pediatric patient with hearing impairment and epilepsy is highly suspicious of a mitochondrial disorder (MID). Were antiepileptic drugs other than valproic acid and levetiracetam prescribed? Were seizures well controlled with levetiracetam?
Which was the cause of the reduced tendon reflexes? Myopathy or neuropathy? Was there also wasting, hypotonia, or fasciculations? Which were the results of nerve conduction studies and the needle electromyography? Were biochemical or single fiber studies carried out with the muscle biopsy? Which were the results? Was creatinekinase elevated? mtDNA mutations usually cause multisystem disease either already at onset of the abnormalities or during the natural course of the disease. Thus, affection of organs can be mild or even subclinical at an early stage of the disease. However, since affection of multiple organs may strongly influence the outcome and prognosis of these patients, it is essential that they are prospectively investigated for multisystem involvement. Particularly important is the thorough investigation of the heart since patients with a mitochondrial disorder and cardiac involvement are prone to develop, cardiomyopathy, conduction defects, and arrhythmias, including sudden cardiac death (SCD). Which were the results of the routine ECG, long-term ECGs, and echocardiography? It is also important to screen MID patients for endocrine abnormalities, hypopituitarism, diabetes, hypo- /hyperthyroidism, hypoaldosteronism, Addison’s disease, and hypogonadism, for renal disease, for hematological abnormalities, and for gastrointestinal involvement.
Overall, this interesting report requires confirmation of the pathogenicity of the variant proposed to be causative, prospective clinical and instrumental investigations for mild or subclinical involvement of organs other than the brain, muscle, and ears, and discussion of possibly mechanisms for the extensive intra- and interfamilial phenotypic heterogeneity of the m.7510T>C variant.
- Kytövuori L, Gardberg M, Majamaa K, Martikainen MH (2017) The m.7510T>C mutation: Hearing impairment and a complex neurologic phenotype. Brain Behav 7:e00859.
- Komlósi K, Maász A, Kisfali P, Hadzsiev K, Bene J, et al. (2013) Erratum tonon-syndromic hearing impairment in a Hungarian family with the m.7510T>C mutation of mitochondrial tRNA(Ser(UCN)) and review of published cases. JIMD Rep9:E1.
- Labay V, Garrido G, Madeo AC, Nance WE, Friedman TB, et al. (2008) Haplogroup analysis supports a pathogenic role for the 7510T>C mutation of mitochondrial tRNA(Ser(UCN)) in sensorineural hearing loss. Clin Genet 73:50-54.
- Del Castillo FJ, Villamar M, Moreno-Pelayo MA, AlmelaJJ, Morera C, et al. (2002) Maternally inherited non-syndromic hearing impairment in a Spanish family with the 7510T>C mutation in the mitochondrial tRNA(Ser(UCN)) gene. J Med Genet 39:e82.
- HutchinTP, Parker MJ, Young ID, Davis AC, PulleynLJ, et al. (2000) A novel mutation in the mitochondrial tRNA(Ser(UCN)) gene in a family with non-syndromic sensorineural hearing impairment. J Med Genet37:692-694.
- Finsterer J, Zarrouk-Mahjoub S, Shoffner JM (2017)MERRFclassification: Implications for diagnosis, and clinical trials. PediatrNeurol80: 8-23.
- Finsterer J (2017) Toxicity of antiepileptic drugs to mitochondria. HandbExpPharmacol 240:473-488.
Citation: Finsterer J, Zarrouk-Mahjoub S (2018) Intra- and inter-familial phenotypic heterogeneity of the m.7510T>C variant. J Neurol Disord 6:381. DOI: 10.4172/2329-6895.1000381
Copyright: © 2018 Finsterer J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 666
- [From(publication date): 0-2018 - Oct 16, 2018]
- Breakdown by view type
- HTML page views: 631
- PDF downloads: 35